175 related articles for article (PubMed ID: 11961667)
41. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts.
Yu DC; Chen Y; Seng M; Dilley J; Henderson DR
Cancer Res; 1999 Sep; 59(17):4200-3. PubMed ID: 10485454
[TBL] [Abstract][Full Text] [Related]
42. Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models.
Voeks D; Martiniello-Wilks R; Madden V; Smith K; Bennetts E; Both GW; Russell PJ
Gene Ther; 2002 Jun; 9(12):759-68. PubMed ID: 12040457
[TBL] [Abstract][Full Text] [Related]
43. Transcriptional tumor-selective promoter targeting of E. coli purine nucleoside phosphorylase for pancreatic cancer suicide gene therapy.
Deharvengt S; Wack S; Aprahamian M; Hajri A
J Gene Med; 2005 May; 7(5):672-80. PubMed ID: 15580629
[TBL] [Abstract][Full Text] [Related]
44. Interleukin-17 receptor-like gene is a novel antiapoptotic gene highly expressed in androgen-independent prostate cancer.
You Z; Shi XB; DuRaine G; Haudenschild D; Tepper CG; Lo SH; Gandour-Edwards R; de Vere White RW; Reddi AH
Cancer Res; 2006 Jan; 66(1):175-83. PubMed ID: 16397230
[TBL] [Abstract][Full Text] [Related]
45. Maspin expression profile in human prostate cancer (CaP) and in vitro induction of Maspin expression by androgen ablation.
Zou Z; Zhang W; Young D; Gleave MG; Rennie P; Connell T; Connelly R; Moul J; Srivastava S; Sesterhenn I
Clin Cancer Res; 2002 May; 8(5):1172-7. PubMed ID: 12006534
[TBL] [Abstract][Full Text] [Related]
46. Rat sodium iodide symporter for radioiodide therapy of cancer.
Mitrofanova E; Unfer R; Vahanian N; Daniels W; Roberson E; Seregina T; Seth P; Link C
Clin Cancer Res; 2004 Oct; 10(20):6969-76. PubMed ID: 15501976
[TBL] [Abstract][Full Text] [Related]
47. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
Akbulut H; Zhang L; Tang Y; Deisseroth A
Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
[TBL] [Abstract][Full Text] [Related]
48. Prostate-restricted replicative adenovirus expressing human endostatin-angiostatin fusion gene exhibiting dramatic antitumor efficacy.
Li X; Liu YH; Lee SJ; Gardner TA; Jeng MH; Kao C
Clin Cancer Res; 2008 Jan; 14(1):291-9. PubMed ID: 18172281
[TBL] [Abstract][Full Text] [Related]
49. Combined ionizing radiation and sKDR gene delivery for treatment of prostate carcinomas.
Kaliberov SA; Kaliberova LN; Buchsbaum DJ
Gene Ther; 2005 Mar; 12(5):407-17. PubMed ID: 15616600
[TBL] [Abstract][Full Text] [Related]
50. Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors.
Raja Gabaglia C; Diaz de Durana Y; Graham FL; Gauldie J; Sercarz EE; Braciak TA
Cancer Res; 2007 Mar; 67(5):2290-7. PubMed ID: 17332360
[TBL] [Abstract][Full Text] [Related]
51. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
[TBL] [Abstract][Full Text] [Related]
52. Relative efficiency of tumor cell killing in vitro by two enzyme-prodrug systems delivered by identical adenovirus vectors.
Lockett LJ; Molloy PL; Russell PJ; Both GW
Clin Cancer Res; 1997 Nov; 3(11):2075-80. PubMed ID: 9815599
[TBL] [Abstract][Full Text] [Related]
53. Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene.
Hughes BW; Wells AH; Bebok Z; Gadi VK; Garver RI; Parker WB; Sorscher EJ
Cancer Res; 1995 Aug; 55(15):3339-45. PubMed ID: 7614469
[TBL] [Abstract][Full Text] [Related]
54. Tightly-regulated suicide gene expression kills PSA-expressing prostate tumor cells.
Peng W; Chen J; Huang YH; Sawicki JA
Gene Ther; 2005 Nov; 12(21):1573-80. PubMed ID: 16034457
[TBL] [Abstract][Full Text] [Related]
55. Antitumor activity of the 16-kDa prolactin fragment in prostate cancer.
Kim J; Luo W; Chen DT; Earley K; Tunstead J; Yu-Lee LY; Lin SH
Cancer Res; 2003 Jan; 63(2):386-93. PubMed ID: 12543792
[TBL] [Abstract][Full Text] [Related]
56. Growth inhibition of prostate cancer by an adenovirus expressing a novel tumor suppressor gene, pHyde.
Steiner MS; Zhang X; Wang Y; Lu Y
Cancer Res; 2000 Aug; 60(16):4419-25. PubMed ID: 10969787
[TBL] [Abstract][Full Text] [Related]
57. Adenovirus-mediated delivery of human IFNgamma gene inhibits prostate cancer growth.
Zhao P; Zhu YH; Wu JX; Liu RY; Zhu XY; Xiao X; Li HL; Huang BJ; Xie FJ; Chen JM; Ke ML; Huang W
Life Sci; 2007 Aug; 81(9):695-701. PubMed ID: 17714738
[TBL] [Abstract][Full Text] [Related]
58. Gene therapy for prostate cancer using the cytosine deaminase/uracil phosphoribosyltransferase suicide system.
Miyagi T; Koshida K; Hori O; Konaka H; Katoh H; Kitagawa Y; Mizokami A; Egawa M; Ogawa S; Hamada H; Namiki M
J Gene Med; 2003 Jan; 5(1):30-7. PubMed ID: 12516049
[TBL] [Abstract][Full Text] [Related]
59. [Clinical application for gene therapy in prostate cancer].
Gotoh A; Kamidono S; Chung LW
Hinyokika Kiyo; 1997 Nov; 43(11):829-33. PubMed ID: 9436031
[TBL] [Abstract][Full Text] [Related]
60. Id-1 expression induces androgen-independent prostate cancer cell growth through activation of epidermal growth factor receptor (EGF-R).
Ling MT; Wang X; Lee DT; Tam PC; Tsao SW; Wong YC
Carcinogenesis; 2004 Apr; 25(4):517-25. PubMed ID: 14688027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
